Alentis Therapeutics Names Roberto Iacone CEO

Basel, Switzerland, July 29, 2020 – Alentis Therapeutics, the Swiss biotech developing breakthrough treatments for fibrotic diseases, announced today that Dr. Roberto Iacone, has been named Chief Executive Officer. Dr. Iacone is a physician-scientist, a serial entrepreneur and brings more than 15 years life science industry experience to Alentis. Most recently while at Versant Ventures, he co-founded Bright Peak Therapeutics and Ridgeline Therapeutics, and was part of the leadership team that built the precision oncology company Black Diamond Therapeutics from inception through to its NASDAQ IPO in three years.  Prior to Versant, Roberto was Roche's Global Head of Rare Diseases Research, where he established numerous collaborations with academic and biotech…

Continue Reading Alentis Therapeutics Names Roberto Iacone CEO

ALENTIS Therapeutics ist gegründet

ALENTIS Therapeutics ist gegründet und erhält CHF 12,5 Mio, um neue Medikamente zur Behandlung fortgeschrittener Lebererkrankungen und Krebs zu entwickeln Basel, 30. April 2019. ALENTIS Therapeutics ("ALENTIS"), ein schweiz-französisches Biotech-Unternehmen entwickelt neue, innovative Medikamente zur Behandlung fortgeschrittener Lebererkrankungen und Krebs. In einer Serie A Finanzierung in Höhe von CHF 12,5 Mio. (€11,1 Mio.; USD 12,5 Mio.) führten die Schweizer Risikokapitalfirmen BioMedPartners und BB Pureos Bioventures das Konsortium an, welchem sich  Bpifrance, Schroder Adveq und der Deutsche High Tech Gründerfonds anschlossen. Dr. Markus L.E.Ewert, MBA wurde zum CEO der neuen Firma ernannt. Er war zuvor Vorstandsmitglied bei Ablynx und trug zu…

Continue Reading ALENTIS Therapeutics ist gegründet

ALENTIS Therapeutics launches

ALENTIS Therapeutics launches, raising CHF 12.5m in a Series A to develop novel therapeutics in advanced liver disease and cancer Basel, April 30, 2019. ALENTIS Therapeutics (“ALENTIS”), a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer, announced today the completion of a Series A financing of CHF 12.5million (Euro 11.1m; USD 12.5m). The Swiss venture capital firms BioMedPartners and BB Pureos Bioventures co-led the round and were joined by Bpifrance, Schroder Adveq and the German High-Tech Gründerfonds (HTGF). Markus L.E. Ewert, PhD, MBA has joined the company as Chief Executive Officer. Markus was previously CBO at…

Continue Reading ALENTIS Therapeutics launches

End of content

No more pages to load